1Division of STD prevention, centers for disease control and prevention. Sex transmitted disease surveillance, 1997. Atlanta: centers for disease control and prevention, 1995.
2Washington AE, Katz P. Cost and payment source for pelvic inflammatory disease: trends and projections, 1983 through 2000 [ J ]. JAMA, 1991,266:2565-2569.
3Rein DB, Kassler WJ, Irwin KE, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial [ J ]. Obstet Gynecol, 2000,95 : 397-402.
4Westrom L. Decrease in incidence of women treated in hospital for acute salpingitis in Sweden [ J ]. Genitourin Med, 1988,64 :59-63.
5Kildea S, Bowden FJ. Reproductive health, infertility and sexually transmitted infections in indigenous women in a remote community in the northern territory[ J]. Aust NZ J Public Health ,2000,24:382-386.
6Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease [ J ]. Expert Rev Anti Infect Ther,2006,4:235-247.
7Savaris RF, Teixeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic in- flammatory disease:a randomized controlled trial [ J ]. Obstet Gynecol,2007,110:53-60.
8Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard muhidrug regimens for the treatment of acute pelvic inflammatory disease [ J ]. J Int Med Res,2003,31:45-54.
9Malhotra M, Sharma JB, Batra S, et al. Ciprofloxaein-tinidazole combination, fiuconazole-azithromicin-secnidazolekit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease:a prospective randomized controlled trial [ J ]. Indian J Med Sci ,2003,57:549-555.
